Stock TLSI TRISALUS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News TriSalus Life Sciences, Inc.

Equities

TLSI

US89680M1018

End-of-day quote Nasdaq
Other stock markets
 23:00:00 11/06/2024 BST 		5-day change 1st Jan Change
6.03 USD +1.17% Intraday chart for TriSalus Life Sciences, Inc. -15.78% -28.64%
06-03 TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial CI
05-30 Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
BU
TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial
CI
Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target
MT
Canaccord Genuity Starts Coverage on TriSalus Life Sciences With Buy Rating, $12 Price Target
MT
TriSalus Life Sciences Launches Warrant Exchange Offer
MT
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
BU
TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M
MT
TriSalus Reports Q1 2024 Financial Results and Business Update
BU
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024
CI
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
BU
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors
CI
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
BU
TriSalus Life Sciences Obtains $50 Million Debt Facility
MT
Trisalus Life Sciences, Inc. and Trisalus Operating Life Sciences, Inc. Enters into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP
CI
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
BU
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC
CI
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
BU
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLSI Stock
  4. News TriSalus Life Sciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW